Brandes Investment Partners LP Sells 36,768 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Brandes Investment Partners LP reduced its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 19.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 151,045 shares of the company's stock after selling 36,768 shares during the period. Brandes Investment Partners LP owned 0.31% of Prestige Consumer Healthcare worth $11,795,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PBH. Aigen Investment Management LP bought a new stake in Prestige Consumer Healthcare in the third quarter valued at $345,000. Huntington National Bank increased its stake in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after purchasing an additional 181 shares in the last quarter. Natixis Advisors LLC increased its position in shares of Prestige Consumer Healthcare by 11.4% during the third quarter. Natixis Advisors LLC now owns 14,581 shares of the company's stock worth $1,051,000 after acquiring an additional 1,491 shares in the last quarter. Quest Partners LLC increased its position in shares of Prestige Consumer Healthcare by 2,582.0% during the third quarter. Quest Partners LLC now owns 11,774 shares of the company's stock worth $849,000 after acquiring an additional 11,335 shares in the last quarter. Finally, Intech Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the third quarter worth about $620,000. 99.95% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PBH shares. Oppenheimer boosted their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. StockNews.com raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Tuesday. DA Davidson boosted their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Canaccord Genuity Group boosted their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of "Moderate Buy" and an average target price of $92.60.

Remove Ads

Prestige Consumer Healthcare Stock Up 0.7 %

PBH stock traded up $0.59 during trading on Thursday, reaching $84.22. The stock had a trading volume of 205,043 shares, compared to its average volume of 257,339. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The company's 50 day moving average is $82.06 and its two-hundred day moving average is $78.49. The company has a market capitalization of $4.17 billion, a price-to-earnings ratio of 19.72, a P/E/G ratio of 2.69 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.